Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $556000.0.

  • Kyntra Bio's Other Non-Current Assets fell 7964.86% to $556000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $556000.0, marking a year-over-year decrease of 7964.86%. This contributed to the annual value of $110.8 million for FY2024, which is 6852.5% up from last year.
  • Kyntra Bio's Other Non-Current Assets amounted to $556000.0 in Q3 2025, which was down 7964.86% from $132.6 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Other Non-Current Assets peaked at $132.6 million during Q2 2025, and registered a low of $556000.0 during Q3 2025.
  • Its 5-year average for Other Non-Current Assets is $25.7 million, with a median of $4.9 million in 2022.
  • Data for Kyntra Bio's Other Non-Current Assets shows a peak YoY increase of 425632.18% (in 2025) and a maximum YoY decrease of 7964.86% (in 2025) over the last 5 years.
  • Kyntra Bio's Other Non-Current Assets (Quarter) stood at $6.7 million in 2021, then dropped by 20.93% to $5.3 million in 2022, then skyrocketed by 1145.29% to $65.8 million in 2023, then soared by 68.52% to $110.8 million in 2024, then plummeted by 99.5% to $556000.0 in 2025.
  • Its last three reported values are $556000.0 in Q3 2025, $132.6 million for Q2 2025, and $108.3 million during Q1 2025.